Certolizumab pegol


Thông tin thuốc gốc
Chỉ định và Liều dùng
Subcutaneous
Rheumatoid arthritis
Adult: Moderate to severe cases: As monotherapy or in combination with methotrexate: Initially, 400 mg (given as 2 injections of 200 mg), repeated at weeks 2 and 4. Maintenance: 200 mg every other week; may consider 400 mg every 4 weeks if clinical response occurs.

Subcutaneous
Ankylosing spondylitis
Adult: Initially, 400 mg (given as 2 injections of 200 mg), repeated at weeks 2 and 4. Maintenance: 200 mg every other week or 400 mg every 4 weeks.

Subcutaneous
Psoriatic arthritis
Adult: As monotherapy or in combination with methotrexate: Initially, 400 mg (given as 2 injections of 200 mg), repeated at weeks 2 and 4. Maintenance: 200 mg every other week; may consider 400 mg every 4 weeks if clinical response occurs.

Subcutaneous
Crohn's disease
Adult: Initially, 400 mg (given as 2 injections of 200 mg), repeated at weeks 2 and 4. Maintenance: 400 mg every 4 weeks.
Hướng dẫn pha thuốc
Add 1 mL sterile water for injection to a vial containing 200 mg to prepare a 200 mg/mL solution. Direct sterile water for injection at the vial wall and swirl gently for about 1 minute. Continue swirling every 5 minutes until fully reconstituted.
Chống chỉ định
Active infection, including chronic or localised infections (e.g. active TB), moderate or severe heart failure (NYHA class III/IV). Concurrent administration of anakinra, abatacept, and live vaccines.
Thận trọng
Patient with haematologic disorders, hypersensitivity reactions (e.g. rash, angioedema, urticaria, dyspnoea, hypotension), mild heart failure (NYHA class I/II) pre-existing or recent central or peripheral nervous system demyelinating disorders, latent TB, chronic hepatitis B virus (HBV) carriers, history of chronic, recurrent or opportunistic infections, malignancy (including history of), risk factors for skin cancer. Patients who are undergoing surgery, exposed to TB, or those who resided or have travelled in areas of endemic TB or endemic mycoses. Pregnancy and lactation.
Phản ứng phụ
Significant: Antinuclear antibody formation, immunogenicity, immunosuppression. Rarely, seizure disorder, peripheral neuropathy, multiple sclerosis, Guillain-Barre syndrome, optic neuritis, pancytopenia, aplastic anaemia, leucopenia, thrombocytopenia, severe hypersensitivity, lupus-like syndrome.
Blood and lymphatic system disorders: Hypercoagulopathy.
Cardiac disorders: Atrial fibrillation, angina pectoris, cardiac arrhythmia, CVA, hypertensive heart disease, ischaemic heart disease, MI, pericarditis, pericardial effusion, TIA.
Eye disorders: Retinal haemorrhage.
Gastrointestinal disorders: Nausea.
General disorders and administration site conditions: Fatigue, fever.
Hepatobiliary disorders: Hepatitis.
Immune system disorders: Urticaria, erythema nodosum.
Infections and infestations: Bacterial (e.g. abscess) and viral (e.g. influenza) infections.
Investigations: Increased hepatic transaminases.
Musculoskeletal and connective tissue disorders: Arthralgia, back pain.
Nervous system disorders: Headache, dizziness.
Psychiatric disorders: Anxiety, bipolar disorder, suicidal tendencies.
Renal and urinary disorders: Urinary tract infection, nephrotic syndrome, renal failure.
Reproductive system and breast disorders: Menstrual disease.
Respiratory, thoracic and mediastinal disorders: Upper respiratory tract infection, cough, nasopharyngitis, bronchitis.
Skin and subcutaneous tissue disorders: Alopecia, dermatitis.
Vascular disorders: Hypertension, vasculitis, haemorrhage.
Potentially Fatal: Serious infections (e.g. sepsis, TB, invasive fungal, bacterial or viral infections), hepatitis B virus (HBV) reactivation (in chronic HBV virus carriers), exacerbation of or new onset CHF, malignancies (e.g. lymphoma, leukaemia, melanoma, Merkel cell carcinoma).
Thông tin tư vấn bệnh nhân
This drug may cause dizziness, if affected, do not drive or operate machinery.
MonitoringParameters
Monitor for signs and symptoms of infection during and after treatment. Evaluate all patients for active and latent TB, HBV infection prior to therapy.
Tương tác
Potentially Fatal: Risk of severe infections and neutropenia with anakinra and abatacept. May diminish the effect of live vaccines.
Lab Interference
May cause falsely elevated aPTT assay results. False-negative for latent tuberculosis test.
Tác dụng
Description: Certolizumab pegol is a pegylated humanised tumour necrosis factor (TNF) antibody fragment that binds specifically to TNF-α, a naturally occurring cytokine that is involved in normal inflammatory and immune responses. It also inhibits the production of lipopolysaccharide-induced TNF-α and interleukin-1β (IL-1β).
Pharmacokinetics:
Absorption: Bioavailability: Approx 80% (range: 76-88%). Time to peak plasma concentration: 54-171 hours.
Distribution: Volume of distribution: 6-8 L.
Excretion: Terminal elimination half-life: Approx 14 days.
Bảo quản
Store between 2-8°C. Protect from light. Do not freeze.
Any unused portions should be disposed of in accordance with local requirements (standard procedures).
Phân loại ATC
L04AB05 - certolizumab pegol ; Belongs to the class of tumor necrosis factor alpha (TNF-alpha) inhibitors. Used as immunosuppressants.
References
Anon. Certolizumab Pegol. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 07/03/2018.

Buckingham R (ed). Certolizumab Pegol. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 07/03/2018.

Cimzia Injection, Solution (UCB, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 07/03/2018.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Certolizumab pegol từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in